Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Biochem Pharmacol. 2021 Mar 11;188:114516. doi: 10.1016/j.bcp.2021.114516

Fig. 7.

Fig. 7.

Schematic diagram showing almonertinib resensitizing ABCB1-overexpressing multidrug-resistant cancer cells to conventional anticancer drugs. The efficacy of ABCB1 substrate anticancer drugs (blue circles) is reduced by ABCB1-mediated drug transport in ABCB1-expressing cancer cells (left). In the presence of almonertinib (white square), almonertinib reduces ABCB1-mediated drug efflux by outcompeting the binding of ABCB1 substrate anticancer drugs to the drug-binding pocket of ABCB1, thus restoring the efficacy of these drugs in ABCB1-expressing cancer cells.